Original researchA phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
Cited by (0)
J-MC and WJ contributed equally.
Previous presentation of data: Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 372P.
Contributors: All authors contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.
Funding: This study was funded by F. Hoffmann–La Roche Ltd.
Competing interests: WJ, MC, MH and MW are the sponsor employees and have sponsor stock ownership. CA and FM are also the sponsor employees. IJ is the sponsor consultant from A4P. AC is the member of the Speaker Bureau of Roche and got research support from Roche.
Patient consent for publication: Not required.
Ethics approval: Local ethics committee approval was obtained.
Provenance and peer review: Not commissioned; externally peer reviewed.
Data availability statement: Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.